Feb 10, 2025 | Chronic conditions, Cost Savings, Drug costs, Flexible spending accounts (FSAs), Health care costs, MedBen Rx, Pharmacogenomics, Rx Costs, Savings
Now available through MedBen Rx, pharmacogenomic testing is transforming health care through safer and more effective personalized medicine. Determining how genes affect a person’s response to drugs not only improves patient outcomes, but it also helps control...
Jan 10, 2025 | Drug costs, Drug reimportation, News
Pharmaceutical companies are planning to increase prices on over 250 brand-name medications in the United States at the beginning of 2025, according to an analysis by health care research firm 3 Axis Advisors. That’s a notable drop from last January, during...
Oct 29, 2024 | Alternative Reimbursement Strategies, Chronic conditions, Client Report, Cost projections, Cost Savings, Direct-to-Employer Contracting, Drug costs, Fair market reimbursement, Forensic claims review, Health care costs, High-cost claims, MedBen Rx, MedBen WellLiving, Prescription, Rx Costs, Transparency, Trend, Wellness
Health care costs in the United States are projected to see their steepest rise in over a decade during 2025, with multiple industry analyses forecasting increases between 7% and 8% year-over-year (see table below). However, MedBen offers solutions that directly...
Oct 15, 2024 | Benefits preservation, Biosimilars, Cost Savings, Drug costs, High-cost claims, Rx Costs, Specialty Drugs
Specialty drugs continue to drive up pharmacy costs, accounting for over 50% of total drug spend for many self-funded health plans, despite being used by a small percentage of patients. But pharmaceutical and administrative solutions are available to help reduce that...
Sep 27, 2024 | Drug advertising, Drug costs, Pharmacy, Rebates, Study
KFF Health News warns consumers not to take TV drug ads at face value: “A 2023 study found that, among top-selling drugs, those with the lowest levels of added benefit tended to spend more on advertising to patients than doctors. ‘I worry that...
Sep 3, 2024 | Biosimilars, Cost Savings, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Savings, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
